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BOOK REVIEWS
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John Wiley & Sons Ltd, xiv+520pp, 1983, £28.50.
ISBN 0 471 90080 x.
The chapters in this book are largely derived from
plenary lectures given during a meeting of the
International Association for Breast Cancer
Research in Denver, Colorado early in 1983. A
number of the useful reference lists at the end of
chapters contain 1983 citations and thus for a
monograph it can be regarded as reasonably topical
Cancer biochemists, biologists and clinicians
interested in breast neoplasia will find the volume
useful as a series of "state of the art" accounts. For
instance Schlom reviews his work on anti-mammary
monoclonal antibodies. Poste describes his and
others data on tumour cell heterogeneity and the
metastatic process and Liotta deals with Laminim
and laminin receptors. Markers of neoplasia with
special emphasis on phosphoproteins are described
by Asch and there is a summary by Taylor-
Papadimitriou of her work on cell lineages in the
normal and malignant breast. Angiogenesis is
reviewed by Gullino and, the experimentally very
difficult area of epithelial mesenchymal interactions
by Sakakura.
There is a section on the molecular analysis of
mammary gland transformation mainly dealing
with mouse mammary tumour virus. Dickson
outlines the difficulties and ascribing function to
the open reading frame in the Mu MTV-LTR,
Diggelman dissects the site of the glucocorticoid
responsive sequence within the Mu MTV genome
and Cardiff critically discusses human-Mu MTV
relationships.
The clinician will derive some possible new
therapeutic approaches and the laboratory worker
new relevant questions. For both, why so much
heterogeneity occurs within tumours, how tumour
clones communicate with each other and whether
tumour cells talk to the stroma remain fascinating
questions. The editors are to be congratulated on
giving us an authoritative review "where we were"
last year in breast cancer biology. However,
monographs such as this cannot keep pace with
molecular biologists.
A. Howell
Department of Medical Oncology,
Christie Hospital & Holt Radium Institute,
Manchester.
Molecular Biology of Mutagens and Carcinogens. B.
SINGER & D. GRUNBERGER, New York, Plenum
Press, 347pp, 1983, £37.50. ISBN 0 306 41430 9.
The first seven chapters of this book are devoted
largely to a discussion of the extent of our present
knowledge of the chemical reactions of different
classes of chemical carcinogens with cellular
macromolecules, mainly nucleic acids. The
treatment of this subject matter is detailed and
comprehensive, the many reactions which occur are
well illustrated, and methods for detecting them are
described in considerable detail. The last two
chapters cover aspects of the biology of
carcinogenesis. The biological consequences of
carcinogen exposure can be profoundly influenced
by the ability of the exposed cell population to
repair or remove damaged DNA bases. The
capacity to repair or remove such DNA damage
varies markedly from tissue to tissue and in
different animal species. Such variations correlate in
some but not all instances with organ specific
carcinogenesis; these aspects are discussed in depth.
The final chapter illustrates the power of molecular
biological techniques. The various methods
available for analysing site directed mutagenesis are
clearly described and there are numerous references
to original articles. A useful appendix contains a
variety of physico-chemical data on nucleic acids
including dissociation constants, UV spectra and
dissociation constants of modified bases. Overall
this should provide a useful reference for many
current workers in the field and a comprehensive
introduction for new entrants.
M. Fox
Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester.